Elsevier

Digestive and Liver Disease

Volume 46, Supplement 5, 15 December 2014, Pages S212-S220
Digestive and Liver Disease

Review Article
Sofosbuvir as backbone of interferon free treatments

https://doi.org/10.1016/j.dld.2014.09.024Get rights and content
Under a Creative Commons license
open access

Abstract

Sofosbuvir is the first-in-class NS5B nucleotide analogues to be launched for hepatitis C virus (HCV) treatment. Its viral potency, pangenotypic activity and high barrier to resistance make it the ideal candidate to become a backbone for several IFN-free regimens. Recent data demonstrated that sofosbuvir either with ribavirin alone or in combination with other direct-acting antivirals (DAAs) as daclatasvir, ledipasvir or simeprevir are able to cure HCV in at least 90% or over of patients. Treatment experienced genotype 3 population may remain the most difficult to treat population, but ongoing DAA combination studies will help to fill this gap. Safety profile of sofosbuvir or combination with other DAAs is good. Resistance to sofosbuvir did not appear as a significant issue. The rationale for using this class of drug and the available clinical data are reviewed.

Keywords

DAAs
Daclatasvir
HCV
IFN-free
NS5B nucleotide inhibitors
Ribavirin
Simeprevir
Sofosbuvir

Cited by (0)